The oral GLP-1 market now has its first real head-to-head data. Lilly's ACHIEVE-3 trial compared orforglipron — the once-daily pill FDA approved on April 1, 2026 as Foundayo — against oral semaglutide (Rybelsus) in adults with type 2 diabetes, and the results published in The Lancet and presented at ADA leave little ambiguity: orforglipron lowered A1C and body weight more than oral semaglutide at every dose pairing tested.
At the top doses, orforglipron 36 mg cut A1C by 2.2 percentage points versus 1.4 for oral semaglutide 14 mg. Across the full dose range presented in June, the gap held — 1.9 to 2.2 points for orforglipron versus 1.1 to 1.4 for oral semaglutide — and 37% of orforglipron patients reached A1C below 5.7% versus 13% on oral semaglutide. Weight loss ran up to 9.2% versus 5.3%.
Below the headline: what this trial was, what an October indirect-comparison analysis added, and the one pharmacological fact most coverage skips — orforglipron is not a peptide at all.
What ACHIEVE-3 was, and was not
ACHIEVE-3 is a randomized head-to-head trial in type 2 diabetes — the same population Rybelsus is approved for — not an obesity trial and not a cardiovascular-outcomes trial. Head-to-head superiority on a primary endpoint against an approved competitor is a high bar, and orforglipron cleared it on glycemic control, with weight loss as a key secondary. Medscape, AJMC and a PMC systematic review all corroborate the same pattern: orforglipron outperformed both oral semaglutide doses (7 mg and 14 mg) on every key endpoint, with an adverse-event profile consistent with the GLP-1 class — predominantly gastrointestinal, and the reason the drug follows a titration schedule starting at 0.8 mg.
The mechanism difference is worth knowing when reading coverage. Semaglutide is a peptide — a modified glucagon-like peptide-1 analog that must be absorbed through a specialized oral formulation with strict dosing conditions (fasted, with water, then wait). Orforglipron is a small molecule that activates the same GLP-1 receptor. That is why Lilly's approval announcement emphasizes it can be taken any time of day without food or water restrictions — the first GLP-1 pill for weight management with that flexibility, and the first new molecular entity approved under FDA's National Priority Voucher Program. Same target, different chemistry, materially different convenience profile.
The October indirect comparison — read the method, not just the number
On October 5, 2026, Drug Topics reported an analysis showing orforglipron produced greater A1C and weight reduction than oral semaglutide 25 mg at 52 weeks. That is a bigger comparator than ACHIEVE-3 used — 25 mg is a higher oral semaglutide dose than the 14 mg maximum approved in the United States, still in development — and critically, the estimate came from an indirect comparison, not a randomized head-to-head.
Indirect comparisons stitch together results across separate trials. They are legitimate evidence, and agencies and journals publish them routinely, but they inherit every difference between the underlying studies: populations, background therapy, titration rules, dropout handling. When you see "X beats Y" this month, check whether the source is a trial or a model. In this case the randomized evidence and the modeled evidence point the same direction, which strengthens the overall picture without making the model a trial.
Separately, on October 1, a Lilly-supported analysis predicted meaningful long-term reductions in type 2 diabetes and cardiovascular risk with orforglipron use — a modeled projection, not observed outcomes, and it should be read as such.
Why this matters beyond the trial
An oral GLP-1 price and access war is the visible consequence. Fierce Pharma now runs a weekly Oral GLP-1 Tracker because the segment is moving that fast — Lilly's pill is approved and launched, Novo's next-generation oral semaglutide is in development, and the indirect-comparison literature is already the battleground both companies are fighting on.
For anyone comparing treatments today, the practical comparisons are not abstract. Our orforglipron vs semaglutide and orforglipron vs tirzepatide pages lay out the evidence, dosing and access differences side by side, and the GLP-1 cost calculator compares real monthly costs across the approved options. Coverage of a trial tells you which endpoint moved; what a treatment costs you is a separate question with its own answer.
One more flag for readers in the gray-market corner of this space: orforglipron is a small molecule, not a peptide, and it is now an FDA-approved prescription drug. Whatever one's views on research-chemical peptide sales, an approved pill with an active launch and a litigation-ready manufacturer is a different legal universe. The compounded-GLP-1 era is closing on its own timeline — that story is tracked in our regulatory timeline.